Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study
Year: 2011
Type: article
Abstract: PURPOSE: Men with high-risk features (extraprostatic extension or high Gleason grade) face a high risk of prostate cancer recurrence after radical prostatectomy. Clinical trials of adjuvant systemic therapy for such patients have been limited. PATIENTS AND METHODS: The SWOG (Southwest Oncology Group) S9921 study randomly assigned 983 men with high-risk features at prostatectomy to receive adjuvant therapy with androgen deprivation (ADT) alone or in combination with mitoxantrone chemotherapy. ADT consisted of goserelin and bicalutamide for 2 years. RESULTS: Although the final primary treatment comparison results are not ready for publication, this article reports results in the ADT-alone control arm with a median follow-up of 4.4 years. For these 481 men, the estimated 5-year biochemical failure-free survival is 92.5% (95% CI, 90 to 95), and 5-year overall survival is 95.9% (95% CI, 93.9 to 97.9). CONCLUSION: The results of this trial, taken in context, make a compelling argument for counseling all high-risk patients with prostate cancer about adjuvant ADT. This article discusses the challenges in the design and implementation of clinical trials to take the next step forward in adjuvant therapy for prostate cancer because of the excellent survival achieved with currently available therapies and highlights the need for better molecular markers to personalize care.
Source: Journal of Clinical Oncology
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: SOUTHWEST ONCOLOGY GROUP, G1033243903, G117886320, G1235982543, SOUTHWEST ONCOLOGY GROUP, G1257575315, G1331445602, G1343089328, G1469275664, G1545560008, G1790576020, G1794831901, G1814228702, G1911575068, G1958973285, G2043432835, Scott & White Community Clinical Oncology Program, G2160369479, G2201816905, G2237949143, G2276667821, G2345882982, G2419449687, G2435896781, G2485941414, G2679961467, G268786457, G2750730928, COLUMBIA UNIVERSITY SOUTHWEST ONCOLOGY GROUP PROGRAM, Ozark Health Ventures, LLC dba Cancer Research for the Ozarks, GRAND RAPIDS CLINICAL ONCOLOGY PROGRAM, SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER, G3126600779, G313314762, G3239274266, G3242537740, Southeast Cancer Control Consortium, Inc, G3295642875, G3334379738, G3337849518, G3350348941, G3484997517, G3521018462, City of Hope Southwest Oncology Group Clinical Trials, G36541222, G3710026009, G3737421695, G379387698, G3939550896, G4110529384, G413878341, SOUTHWEST ONCOLOGY GROUP--CLINICAL TRIALS, G425646771, G4271794948, Southwest Oncology Group, G4292856267, G444114835, Southwest Oncology Group, G4499432180, G4527800867, SOUTHWEST ONCOLOGY GROUP, G5187432406, G5264753430, G5566132837, G591690631, SOUTHWEST ONCOLOGY GROUP, SOUTHWEST ONCOLOGY GROUP, G648555781, Cancer and Leukemia Group B, G6723594983, G6741197049, SOUTHWEST ONCOLOGY GROUP, G6782300252, SOUTHWEST ONCOLOGY GROUP STUDIES, G6943608702, G7230571265, G758084519, Virginia Mason Community Clinical Oncology Program, G7860541851, G8116866424, G8156375866, Eastern Cooperative Oncology Group Operations Office, G8413228103, G860872252, SOUTHWEST ONCOLOGY GROUP, G8740717309, PARTICIPATE AS MEMBER OF SOUTHWEST ONCOLOGY GROUP, G933283670, G937543590, Southwest Oncology Group/University of California, Davis
OpenAlex ID: W2128521057